Kerry Group to Acquire Lactase Enzyme Business from Chr. Hansen and Novozymes

Novozymes and Chr. Hansen Combine to Form Novonesis

January 29, 2024

Biotechnology

On January 29, 2024 Novozymes and Chr. Hansen completed a statutory merger to create Novonesis, a global biosolutions company focused on enzymes, cultures and microbial solutions. The combined group will employ around 10,000 people worldwide and have pro forma annual revenue of approximately EUR 3.7 billion, with targeted synergies across food & health and planetary health portfolios.

Chr. Hansen Acquires UAS Laboratories LLC

June 9, 2020

Biotechnology

Chr. Hansen Holding A/S has agreed to acquire 100% of UAS Laboratories LLC from Lakeview Equity Partners, the UAS management team and other shareholders for USD 530 million (net of tax assets). The acquisition (UAS Labs: ~230 employees, ~USD 85m revenue and >USD 30m EBITDA in 2020) strengthens Chr. Hansen’s microbial platform and Human Health business by adding probiotic strains, two GMP production facilities in Wisconsin, and increased fermentation and downstream processing capacity.

Kerry Group Acquires c-LEcta GmbH from SHS

February 15, 2022

Biotechnology

Kerry Group has acquired Leipzig-based enzyme engineering company c-LEcta GmbH from growth investor SHS. c-LEcta, a developer and supplier of enzyme and biotech products for regulated food, pharmaceutical and chemical markets with over one hundred employees, will be used by Kerry to expand its biotechnology capabilities and international presence in bio-actives for food and pharma.

Kemin Industries Acquires CJ Youtell Biotech

September 23, 2025

Biotechnology

Kemin Industries has acquired CJ Youtell Biotech, the enzymes and fermentation subsidiary of CJ Bio, gaining full ownership of CJ Youtell’s fermentation plants and enzyme product portfolio. The acquisition adds fermentation capacity in Shandong and Hunan, China and expands Kemin’s global enzyme R&D, manufacturing and product offerings across animal feed, food, aquaculture and industrial end markets.

BioMarin Acquires Inozyme Pharma

May 16, 2025

Biotechnology

BioMarin Pharmaceutical Inc. completed its acquisition of Inozyme Pharma, Inc. in an all-cash transaction valued at approximately $270 million ($4.00 per share). The deal adds Inozyme's late-stage enzyme replacement therapy INZ-701 for ENPP1 Deficiency to BioMarin's enzyme-therapy portfolio and is expected to accelerate development toward potential regulatory approval.

Bain Capital and Cinven to Acquire Lonza Specialty Ingredients

February 8, 2021

Manufacturing

Bain Capital Private Equity and Cinven have entered into definitive agreements to acquire Lonza Specialty Ingredients (LSI), a division of Lonza AG, for a total enterprise value of CHF 4.2 billion. LSI, headquartered in Basel, Switzerland, is a global provider of specialty chemicals for microbial control with ~2,800 employees, and the consortium intends to invest in R&D, bolster production capabilities and use LSI as a platform for buy-and-build consolidation in the sector; the transaction was expected to close in H2 2021.